Pharmaceutical manufacturers are advancing secondary indication trials for GLP-1 compounds, targeting cardiovascular disease, kidney health, and liver conditions.
Payer Coverage and Pricing Models
Health insurers and national health authorities are evaluating long-term cost offsets against high upfront treatment expenditures.
Manufacturing Scale
Contract development and manufacturing organizations are investing heavily in sterile fill-finish capacity to meet global demand surges.